
Supriya Lifescience Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- The company targets 20%+ annual revenue growth driven by a blended portfolio including existing products, new product launches, and CMO/CDMO activities.
- Peak revenue from the DSM contract is expected around INR60-70 crores with anticipated 20-25 metric tons supply in FY '25.
- New product launches in regulated markets, including anaesthetic, anti-diabetic, and anti-anxiety categories, are expected to significantly contribute starting FY '25.
- CMO/CDMO segment is forecasted to contribute 18-20% of total revenue by FY '27, with Amarnath facility advancing capacity.
- The oral cancer detection kit is scheduled for launch in ~2 years following clinical trials.
- Capacity utilization currently at ~86%, with new modules (Amarnath and Module E) commissioning by Q2 FY '25; full-scale production to take 2-3 years.
- Regulated market share is increasing, stabilizing revenue with diversified product basket mitigating seasonality effects.
See what Supriya Lifescience management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The company is currently debt-free with strong cash positions.
- They do not utilize any working capital limits except for letters of credit and bank guarantees.
- No borrowings have been utilized in the last six months.
- There is no mention of any planned fundraising through debt or equity in the current or near future.
- The company appears focused on organic growth funded through internal accruals and careful capex planning (INR 100 crores planned for FY25).
See what Supriya Lifescience management said on order book — free account, 30 seconds.
Capex plans
Yes- Capex of about INR 100 crores anticipated in FY25, mainly for the Ambernath facility and new Module E.
- Module E is expected to be commissioned by end of the current month, with commercial production starting by Q2 FY25.
- Ambernath facility is also scheduled to be ready by Q2 FY25 to expand CMO and CDMO activities.
- An additional capex of approximately INR 75 crores for Ambernath has already been spent.
- Debottlenecking activities are ongoing to enhance capacity at the current product basket.
- The new capacities at Lote will reach around 1020 KL, and Ambernath will add approximately 200 KL.
- Capex and capacity expansion aim to support the scaling up of CMO/CDMO projects, expecting 18-20% of revenue from these by FY27.
Track Supriya Lifescience — get its next earnings analysis in your feed
How does Supriya Lifescience rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Supriya Lifescience rank in Pharmaceuticals & Biotechnology?
Compare Supriya Lifescience against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Supriya Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem